XCR1+ DCs are critical for T cell-mediated immunotherapy of chronic viral infections

The contribution of cross-presenting XCR1+ dendritic cells (DCs) and SIRPα+ DCs in maintaining T cell function during exhaustion and immunotherapeutic interventions of chronic infections remains poorly characterized. Using the mouse model of chronic LCMV infection, we found that XCR1+ DCs are more r...

Full description

Saved in:
Bibliographic Details
Published inCell reports (Cambridge) Vol. 42; no. 2; p. 112123
Main Authors Domenjo-Vila, Eva, Casella, Valentina, Iwabuchi, Ryutaro, Fossum, Even, Pedragosa, Mireia, Castellví, Quim, Cebollada Rica, Paula, Kaisho, Tsuneyasu, Terahara, Kazutaka, Bocharov, Gennady, Argilaguet, Jordi, Meyerhans, Andreas
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 28.02.2023
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The contribution of cross-presenting XCR1+ dendritic cells (DCs) and SIRPα+ DCs in maintaining T cell function during exhaustion and immunotherapeutic interventions of chronic infections remains poorly characterized. Using the mouse model of chronic LCMV infection, we found that XCR1+ DCs are more resistant to infection and highly activated compared with SIRPα+ DCs. Exploiting XCR1+ DCs via Flt3L-mediated expansion or XCR1-targeted vaccination notably reinvigorates CD8+ T cells and improves virus control. Upon PD-L1 blockade, XCR1+ DCs are not required for the proliferative burst of progenitor exhausted CD8+ T (TPEX) cells but are indispensable to sustain the functionality of exhausted CD8+ T (TEX) cells. Combining anti-PD-L1 therapy with increased frequency of XCR1+ DCs improves functionality of TPEX and TEX subsets, while increase of SIRPα+ DCs dampened their proliferation. Together, this demonstrates that XCR1+ DCs are crucial for the success of checkpoint inhibitor-based therapies through differential activation of exhausted CD8+ T cell subsets. [Display omitted] •XCR1+ DCs are more functional and less prone to LCMV infection than SIRPα+ DCs•Expanding XCR1+ DCs via Flt3L or delivering XCR1-targeting Ag improve virus control•Anti-PD-L1 treatment increases XCR1+ DC numbers and IL-12 production•XCR1+ DCs promote TEX functionality but are dispensable for TPEX proliferation burst Domenjo-Vila et al. show that XCR1+ DCs are crucial in augmenting exhausted CD8+ T cell effector functions during immunotherapeutic interventions in chronic virus infections. Increased T cell functionality leads to reduced virus loads. XCR1+ DCs should be among the preferential targets in immunotherapeutic cure strategies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2211-1247
2211-1247
DOI:10.1016/j.celrep.2023.112123